natgillin/translations-raw huggingface dataset:
RF amplifiers; and 
RF pojačala; 1 e. < SIM karticu.
conjugating a maytansinoid to the antibodies having linkers bound thereto in the purified first mixture by reacting the antibodies having linkers bound thereto with a maytansinoid in a solution having a pH of 4 to 9 to prepare a second mixture comprising (i) antibodies chemically coupled through the linker to the maytansinoid, (ii) free may tansinoids, and (iii) reaction by-products, and 
(c) konjugacije maitanzinoida sa antitijelima koja imaju za sebe vezane linkere u pročišćenoj prvoj smjesi putem reakcije antitijela koja imaju za sebe vezane linkere sa maitanzinoidom u otopini koja ima pH od 4 do 9 da bi se pripremila druga smjesa koja sadrži (i) antitijelo kemijski spojeno preko linkera za maitanzinoid, (1i) slobodan maitanzinoid i (iii) sporedne proizvode reakcije, 1
piperidine monohydrochloride crystal. U(eq) is defined as one third 
U(eq) se definira kao jedna trećina U" tenzora. x
On the contrary the prior art had used (while adopting the corresponding processes) plants in which, like in figure 1, the hot rolling mills are provided with a plurality of stands of the High-Four tandem-type. 
Nasuprot tome u prethodnoj tehnici su korištena (uz prihvaćanje odgovarajućih postupaka) postrojenja u kojima su, kao na slici 1, osigurane vrele valjaonice sa većim brojem postolja,,High-Four" tandem tipa.
In a preferred embodiment of this first aspect of the invention, the amino acid sequence of (a) of the DNA polymerase chimera of the invention encodes a φ29 type DNA polymerase having modification in the exonuclease domain, wherein said modified DNA polymerase has preferably, less than 10% of exonuclease activity and, more preferably, less than 1% of exonuclease activity than the corresponding naturally occurring DNA polymerase or “wild type”. 
DNK polimeraza himera prema bilo kojem zahtjevu od 1 do 9, gdje 029 tip DNK polimeraza od (a) ima modifikaciju u eksonukleaznoj domeni i gdje navedena modificirana DNK polimeraza ima manje od 1% eksonukleaznog djelovanja od odgovarajućeg djelovanja koje se prirodno pojavljuje u DNK polimerazi, DNK polimeraza himera prema zahtjevu 10, gdje modificiran 029 tip DNK polimeraza od (a) ima manje od 1% of eksonukleaznog djelovanja od odgovarajuće DNK polimeraze koja se pojavljuje prirodno.
parsing, by the processor, a mode index indicating one among the candidate intra prediction modes, when the mode prediction flag indicates one of the candidate intra prediction modes is used to determine the intra prediction mode of the current block; 
- < dobivanje iz toka bitova, zastavice najvjerojatnijeg načina, koja označava da li je upotrijebljen jedan od kandidata načina unutrašnjeg predviđanja, za određivanje načina unutrašnjeg predviđanja trenutnoga bloka;
Thus, the invention also relates to the use of a compound according to the invention for the manufacture of a medicament for the treatment of androgen insufficiency or a medicament for testosterone replacement. 
Prema tome, ovaj izum se također odnosi na upotrebu spoja prema ovom izumu u proizvodnji medikamenta za liječenje androgenske insuficijencije ili medikamenta za testosteronsku zamjensku terapiju.
A fabric softening composition, comprising: as component A, at least one tertiary or quaternary ammonium salt, selected from compounds of formulae (I) and (II): 
Pripravak za omekšavanje tkanine naznačen time da sadrži a) kao komponentu A barem jednu tercijarnu ili kvarternarnu amonijevu sol, koja je odabrana od spojeva s formulama (1) i (II):
In yet another aspect, the invention is directed to an isolated polynucleotide encoding a chimeric polypeptide having the sequence of SEQ ID No.:2. 
Antitijelo u skladu sa zahtjevom 1 ili zahtjevom 2, naznačeno time, da navedeno antitijelo sadrži izolirani polipeptid koji sadrži sekvencu teškog lanca varijabilne regije od SEQ ID NO: 40.
Process according to claim 1, characterized in that at least part of the precipitated divalent metal ion carbonate product obtained in step (g) is subjected to at least one further carbonation step, where the at least part of the precipitated divalent metal ion carbonate product obtained in step (g) is first mixed with an aqueous suspension of divalent metal ion hydroxide that was obtained by slaking high-purity divalent metal ion oxide to obtain a resulting reaction mixture and then the resulting reaction mixture is subjected to carbonation. 
Vodena suspenzija ili osušeni istaloženi karbonat dvovalentnog metalnog iona u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što se u najmanju ruku dio istaloženog karbonata dvovalentnog metalnog iona kao produkta dobiven u koraku (g) podvrgava najmanje jednom dodatnom koraku karbonatiranja, gdje u najmanju ruku dio istaloženog karbonata dvovalentnog metalnog iona kao produkta dobiven u koraku (g) se najprije pomiješa s vodenom suspenzijom hidroksida dvovalentnog metalnog iona dobivenog gašenjem oksida dvovalentnog metalnog iona visoke čistoće kako bi se dobilo rezultirajuću reakcijsku smjesu, a zatim se rezultirajuću reakcijsku smjesu podvrgava karbonatiranju.
or a salt thereof, to yield the compound of Formula 1 or a salt thereof; and optionally converting the compound of Formula 1 or a salt thereof into a pharmaceutically acceptable complex, salt, solvate or hydrate, wherein R1 and R2 in Formula 8 are as defined above in Formula 1, and R5 in Formula 8 is hydrogen atom, C1-12 alkyl, C3-12 cycloalkyl, or aryl-C1-6 alkyl. 
(b) dekarboksiliranju spoja Formule 7, ili njegove soli, kako bi se dobilo spoj Formule I, ili njegovu sol; i (c) izbornom prevođenju spoja Formule 1, ili njegove soli, u njegov farmaceutski prihvatljiv kompleks, sol, solvat ili hidrat, gdje R! i R* u Formuli 6 i Formuli 7 su definirani kao za Formulu 1.
The method of claim 1, wherein the daily amount of biotin administered to the subject is at least 250 mg. 
Biotin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što dnevna količina biotina koja se daje pacijentu iznosi najmanje 250 mg.
decreasing the total amount of soluble amyloid-B in the retinal ganglion cell layer of a subject suffering from glaucoma, optic neuritis, or lattice dystrophy; or 
smanjivanje ukupne količine topljivog amiloida-B u sloju ganglijskih stanica u mrežnici kod subjekta koji boluje od glaukoma, optičkog neuritisa ili retikularne distrofije; ili
The method of claim 1, wherein the subject is selected from the group consisting of a subject having an AN count of greater than or equal to 3 at baseline, a subject who is female, a subject who is over 40 years old, a subject who is a smoker, or any combination thereof. 
Anti-TNFa protutijelo za uporabu prema bilo kojem od zahtjeva 1-9, naznačeno time, da se subjekt bira iz skupine koja se sastoji od subjekta koji ima početni broj AN veći ili jednak 3, subjekta koji je ženska osoba, subjekta koji je stariji od 40 godina, subjekta koji je pušač, 1li bilo koje od njihovih kombinacija.
rheumatic diseases or autoimmune diseases or joint diseases, which coincide with inflammatory, allergic and/or proliferative processes, 
reumatske bolesti ili autoimune bolesti ili bolesti zglobova, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
In yet another embodiment, the invention is directed to a process for preparing Compound 2: wherein R5 and R6 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, alkylaryl, arylalkyl, heterocyclic and heteroaryl groups, or R5 and R6, together with the nitrogen to which they are attached, form a 3- to 6-membered heterocyclic compound containing 1-4 heteroatoms, said process comprising: 
gdje svakog od Rs i Rg se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne, heterocikličke i heteroarilne skupine, ili Rs i R4, zajedno s dušikom na kojeg su vezani, tvore 3- do 6-eročlani heterociklički spoj s 1 -4 heteroatoma, naznačen time što navedeni postupak se sastoji u:
HPLCJasco PU-2080 plus, intelligent HPLC pump equipped with Jasco LG-2080-02 ternary gradient unit and Jasco DG-2080-53 3 line degasser (or equivalents). 
HPLCJasco PU-2080 plus, inteligentna HPLC pumpa opremljena s Jasco LG-2080-02jedinicom trojnog gradijenta te Jasco DG-2080-53 3 linijskim rasplinjačem (ili ekvivalentima).
As shown in FIG. 32, the ester compound of Formula 27 is next saponified to its corresponding carboxylic acid of Formula 28 (where R2═CH2CH(CH3)2; P3=CBZ; R11═H; R12═PhOMe in generalized formula V of Scheme 8). 
Kao stoje prikazano na slici 32, spoj cstera formule 27 sc sljedeći saponificira u svoju odgovarajući karboksilnu kiselinu formule 28 (gdje R>=CH2CH(CH;),; P3=CBZ; R,,=H; R;»=PhOMe u općoj formuli V iz sheme 8).
optionally wherein: the Gram-negative organism is selected from the group consisting of Enterobactericeae, Bacteroidaceae, Vibrionaceae, Pasteurellae, Pseudomonadaceae, Neisseriaceae, Rickettsiae, Moraxellaceae, any species of Proteeae, Acinetobacter spp., Helicobacter spp., and Campylobacter spp.; or 
Spoj za uporabu prema patentnom zahtjevu 3, ili uporabu prema patentnom zahtjevu 4, naznačen time da je zaraza uzrokovana Gram-negativnom bakterijom izabranom od Enterobactericeae, Bacteroidaceae, Vibrionaceae, Pasteurellae, Pseudomonadaceae, Neisseriaceae, Rickettsiae, Moraxellaceae, bilo koja vrsta Proteeae, Acinetobacter spp., Helicobacter spp., i Capylobacter spp.
The implant according to claim 5, wherein the metallic base comprises at least 90% by weight of titanium. 
Obloženi metalni implantat u skladu s patentnim zahtjevom 5, pri čemu implantat sadrži najmanje 90% mase titana ifili slitine titana.
The Compound A of claim 1 that is at least 99% free of other solid forms of compound A. 
Spoj A prema zahtjevu 1, naznačen time, da je najmanje 99% bez drugih krutih oblika spoja A.
The process of claim 2, wherein said second base is selected from the group consisting of triethylamine; 1,5-diazabicyclo[4,3,0]non-5-ene 1,4-diazabicyclo[2,2,2]octane; 1,8-diazabicyclo[5,4,0]undec-7-ene; and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 37, naznačen time što navedenu drugu bazu se bira iz skupine koju čine trietilamin; 1,5-diazabiciklo[4.3.0]non-5-en; 1,4-diazabiciklo[2.2.2]oktan; 1,8-diazabiciklo[5.4.Ojundec-7-en; i smjese 2 ili više njih.
An antibody or antigen-binding fragment or pharmaceutical composition according to item 38, wherein the use in medicine is the use in a method for the treatment of an inflammatory disease, of an autoimmune disease, of a respiratory disease, of a metabolic disorder, of an epithelial mediated inflammatory disorder, fibrosis or of cancer. 
Protutijelo ili njegov fragment koji veže antigen ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 6, naznačeni time, da se kod uporabe u medicini radi o uporabi u postupku liječenja upalne bolesti, autoimune bolesti, respiratorne bolesti, metaboličkog poremećaja, upalnog epitelno posredovanog poremećaja, fibroze ili raka.
The process of claim 2, wherein said second base is selected from the group consisting of triethylamine, 1,5-diazabicyclo[4,3,0]non-5-ene 1,4-diazabicyclo[2,2,2]octane, and 1,8-diazabicyclo[5,4,0]undec-7-ene, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 37, naznačen time što navedenu drugu bazu se bira iz skupine koju čine trietilamin; 1,5-diazabiciklo[4.3.0]non-5-en; 1,4-diazabiciklo[2.2.2]oktan; 1,8-diazabiciklo[5.4.Ojundec-7-en; i smjese 2 ili više njih.
A pharmaceutical combination that comprises a pharmaceutical formulation according to claim 1 and an anti-diabetic, wherein the anti-diabetic is a sulfonylurea, thiazolidinedione, alpha glucosidase inhibitor, meglitinide, glucagon-like peptide (GLP) agonist, insulin, amylin agonist, fructose 1,6-bis phosphatase inhibitor, insulin secretagogue, insulin sensitizer, glucokinase activator, glucocorticoid antagonist, AMP kinase activator, modulators of the incretin pathway such as incretin secretagogue, incretin mimic, incretin potentiator, bile acid sequestrant or bile acid receptor agonist such as TGR5 agonist, dopamine receptor agonist, aldose reductase inhibitor, PPARY agonist, PPARa agonist, PPARδ antagonist or agonist, PPARa/Y dual agonist, 11-B-HSD-1 inhibitor, dipeptidyl peptidase IV (DPP4) inhibitor other than saxagliptin, SGLT2 inhibitor other than dapagliflozin, glucagon-like peptide-1 (GLP-1), GLP-1 agonist, or PTP-1B inhibitor. 
Farmaceutska kombinacija naznačena time da sadrži farmaceutsku formulaciju prema zahtjevu 1 i anti-dijabetičko sredstvo, pri čemu anti-dijabetičko sredstvo je sulfonilurea, tiazolidindion, inhibitor alfa glukozidaze, meglitinid, agonist glukagonu sličnog peptida (GLP), inzulin, agonist amilina, inhibitor fruktoza 1,6-bis fosfataze, sekretagog inzulina, senzitizator inzulina, aktivator glukokinaze, glukokortikoidni antagonist, aktivator AMP kinaze, modulatori inkretinskog puta kao što je sekretagog inkretina, mimetik inkretina, potencijator inkretina, sekvestrant žučne kiseline ili agonist receptora žučne kiseline kao što je agonist TGR5, agonist receptora dopamina, inhibitor aldoza reduktaze, PPARY agonist, PPARa agonist, PPARδ antagonist ili agonist, PPARa/Y dual agonist, 11-B-HSD-1 inhibitor, inhibitor dipeptidil peptidaze IV (DPP4) različit od saksagliptina, inhibitor SGLT2 različit od dapagliflozina, glukagonu sličan peptid-1 (GLP-1), agonist GLP-1, ili inhibitor PTP-1B.
Catalytic Hydrogenation of the Compound of the Formula (III) 
(97) Broj objave europskog patenta:
As shown in Fig. 2 electronic control means, such as for example a microprocessor controls the operation of the thermoblocks (heating), the pumps and the different valves as shown in Fig. 1. 
Kao što je prikazano na SL 2, elektronski kontrolni sustav, poput primjerice mikroprocesora, kontrolira rad termoblokova (grijanje), pumpi i različitih ventila, kao što je prikazano na SI. 1.
A pharmaceutical composition according to claim 14, which is in the form of aqueous suspension. 
Farmaceutski pripravak prema patentnom zahtjevu 15, naznačen time da je u obliku vodene suspenzije.
o′)—Switching off the cooling and lubrication unit; 
o ́) - zaustavljanje sustava hlađenja i podmazivanja (200);
The combination for the use of any one of claims 8, parts (v) to (xi), and 9 to 13, wherein the cancer is selected from the group consisting of breast cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, colorectal carcinoma, prostate cancer, renal cell carcinoma, melanoma, hepatocellular carcinomas, cervical cancer, sarcomas, brain tumors, gastric cancers, gastrointestinal cancers, esophageal cancer, bladder cancer multiple myeloma, leukemia, and lymphoma. 
Sastav za uporabu u skladu s patentnim zahtjevom 1, pri čemu je karcinom odabran iz grupe koja se sastoji od karcinoma jetre, karcinoma glave i vrata, karcinoma gušterače, karcinoma želuca, karcinoma bubrega, sarkoma, multiplog mijeloma, metastatskog karcinoma dojke, leukemije, limfoma, karcinoma jednjaka, tumora mozga, glioma, karcinoma mokraćnog mjehura, karcinoma endometrija, karcinoma štitnjače, karcinoma žučnih vodova, malignog tumora kostiju, karcinoma oka (retinoblastoma), karcinoma žučnog mjehura, karcinoma hipofize, karcinoma kolona, kolrektalnog karcinoma, karcinoma žlijezde slinovnice, nazofaringealnog karcinoma, karcinoma dojke, karcinoma pluća, karcinoma prostate, karcinoma jajnika, neuroblastoma, karcinoma cerviksa, melanoma i karcinoma kože.
Whilst the invention has been described with reference to a preferred embodiment, it will be appreciated that various modifications are possible within the scope of the invention as defined in the following claims. A delayed release drug formulation for oral administration to deliver a drug to the colon of a subject, said formulation comprising: a core and a coating for the core, the core comprising a drug and the coating comprising an outer layer and an inner layer, wherein the outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold at pH 6 or above, and wherein the inner layer comprises a third polymeric material which is non-ionic polymer that is soluble in intestinal fluid or gastrointestinal fluid, and at least one additive selected from a buffer agent and a base. 
HR P20180068 T1 PATENTNI ZAHTJEVI Formulacije lijeka s produljenim oslobađanjem za oralnu primjenu za isporuku lijeka u debelo crijevo pacijenta, pri čemu spomenuta formulacija sadrži jezgro, to jezgro sadrži lijek i prevlaku za jezgru, jezgru koja sadrži lijek i ovojnicu koja sadrži vanjski i unutarnji sloj, pri čemu vanjski sloj sadrži smjesu prvog polimernog materijala koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima graničnu vrijednost pH na pH 6,5 ili više, 1 pri čemu unutarnji sloj sadrži treći polimerni materijal koji je topiv u crijevnoj tekućini, spomenuti treći polimerni materijal je polimer polikarboksilne kiseline koji je bar djelomično neutraliziran, pri čemu bar 10% skupina karboksilne kiseline polimera polikarboksilne kiseline su u obliku aniona karboksilata.
The method of claim 9, wherein the ActRIIa-Fc fusion protein is a dimer formed of two polypeptides that each comprise the amino acid sequence of SEQ ID NO:12 joined by disulfide bonding. 
Farmaceutska smjesa iz zahtjeva 1 ili 2, naznačena time, što se ActRIla-Fc fuzijski protein rekombinantno eksprimira u CHO stanicama, uz korištenje TPA liderske sekvence SEQ ID NO: 9.
A compound of Formula (I) according to claim 1 wherein 
Spoj Formule (I) u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 3,
According to the second embodiment of the process according to the invention, step b) therefore preferably comprises: a first separation step S 2 which consists in the separation of the said mixture of products in a main column C 2 into a fraction F 2 at the top of column C 2 and into fraction C at the bottom of column C 2, 
Postupak prema bilo kojem od zahtjeva 1 do 6, naznačen time da korak b) obuhvaća: - prvi korak odvajanja S2 koji se sastoji u odvajanju navedene mješavine produkata unutar glavne kolone C2 u frakciju F2 na vrhu kolone C2 i u frakciju € na dnu kolone C2,
it has a decreased sialylation degree with at least a 15% lower amount of NeuNAc on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the protein molecule of the protein molecules in said protein molecule composition than the same amount of protein molecules of at least one protein molecule composition of the same protein molecule isolated from CHOdhfr- [ATCC No. 
CRL-9096 (CHOdhfr-) kada se tamo eksprimira; i/ili – sadrži količinu fukoze na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli protutijela kod navedenih molekula protutijela u navedenom pripravku s molekulom protutijela koja je najmanje 5% manja u usporedbi s istom količinom molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.
Uncontrolled diabetes increases the risk of cardiovascular diseases such as heart attack and stroke. 
Nenadzirani dijabetes povećava rizik od kardiovaskularnih bolesti poput srčanog udara i moždanog udara.
Typical cellulose ethers are hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methyl-cellulose. 
Uobičajeni esteri celuloze su hidroksiceluloza, hidroksipropilceluloza, hidroksipropilmetilceluloza, metilcetuloza.
In other words, the present invention also discloses a compound according to the invention and/or a pharmaceutically usable derivative, salt, solvate, tautomer or stereoisomer thereof, for use in the treatment of diseases which are influenced by inhibition of ATM kinase. 
Spoj prema jednom od zahtjeva 1 do 3 i/ili njegov farmaceutski upotrebljiv derivat, sol, solvat, tautomer ili stereoizomer, naznačen time što je za uporabu u liječenju raka, tumora i/ili metastaza.
A pharmaceutical composition comprising a combination of the compound of claim 1, and 1 to 3 other agents useful in treating Parkinson's disease in a pharmaceutically acceptable carrier. 
Farmaceutska smjesa, naznačena time, što sadrži kombinaciju spoja iz zahtjeva 11 1 do 3 druga sredstva korisna 7a liječenje Parkinsonove bolesti, u farmaceutski
Fig. 25 shows an automated packing machine for packing the packaging according to the invention. 
prikazuje automatizirani stroj za pakiranje s kojim se obavlja pakiranje koje je u skladu s ovim izumom.
A compound of any of claims 1 to 9 for use according to claim 16 wherein pain is a neuropathic pain syndrome or an inflammatory pain syndrome. 
Spoj iz bilo kojeg od patentnih zahtjeva 1 do 9 za upotrebu prema patentnom zahtjevu 16 pri čemu bol jest sindrom neuropatske boli ili sindrom upalne boli.
In one embodiment, the DE loop comprises the underlined portion of SEQ ID NO: 39. 
Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što je valin na položaju 5 u petlji DE (SEQ ID NO:
Composition according to one of the preceding claims, wherein the isomer of inositol is myo-inositol, scyllo-inositol, muco-inositol, D-chiro-inositol, neo-inositol, L-chiro-inositol, allo-inositol, epi-inositol, and cis-inositol or mixtures thereof. 
Meka kapsula prema jednom od prethodnih zahtjeva, naznačena time da inozitol je: mio-inozitol, scilo-inozitol, muko-inozitol, D-kiro-inozitol, neo-inozitol, L-kiro-inozitol, alo-inozitol, epi-inozitol i cis-inozitol ili njihove mješavine.
The method according to claim 1, wherein the gel former is selected from the group consisting of vinyl homopolymers and copolymers, cellulose derivatives, and mixtures thereof. 
Pripravak za primjenu prema bilo kojem od prethodnih zahtjeva, naznačen time, što je tvar za formiranje gela odabrana iz skupine koja se sastoji od vinilnih homopolimera i kopolimera, derivata celuloze i njihovih smjesa.
With this known process it is also possible to incorporate a filter, or even multi-stage filters, in the nozzle arrangement. 
Tim poznatim postupkom u napravu s mlaznicom se može također ugraditi i filtar, ili čak višefazni filtri.
a magnetic system comprising a plurality of quasi-de coils positioned around the confinement chamber, the first and second formation sections, and the first and second divertors, first and second set of quasi-dc mirror coils positioned between the confinement chamber and the first and second formation sections; 
Sustav prema zahtjevima 1, 4 i 5, naznačen time, da dodatno obuhvaća treći i četvrti komplet zrcalnih zavojnica između svakog od prvog i drugog tvorbenog dijela (200) te prvog i drugog preusmjerivača (300).
The variant, recombinant human B-glucocerebrosidase protein according to claim 7 wherein the extended apparent half-life is measured after incubation at conditions of neutral pH and 37°C over a period of three hours. 
Varijanta, rekombinantnog ljudskog proteina B-glukocerebrozidaze prema zahtjevu 7, naznačena time da se produljeni poluvijek mjeri nakon inkubacije u uvjetima neutralnog pH i 37°C tijekom perioda od tri sata.
In some embodiments, a subject genetically modified host cell is in vitro. 
Genetički modificirana stanica domaćin, koja je eukariotska stanica, naznačena time što sadrži:
The process of claim 24, wherein the first acid is hydrochloric acid. 
Postupak prema patentnom zahtjevu 2, pri čemu je kiselina u koraku vc, klorovodična kiselina.
Preferably, the tangent of the arc of trajectory Q and the tangent of the arc of the rotary machine R coincide at the discharge point whereat suction cups 8, 9 and gripper 10 release the pouch 102 and spout 103, and the rotary machine grasps the pouch 102 and spout 103 . 
Nakon toga točka Q, koja je prikazana na slici 2, slijedi putanju koja uglavnom opisuje obodni luk, tako da je relativna brzina usisnih čašica 8, 9 i naprave za hvatanje 10 u odnosu na rotacijski stroj jednaka i suprotna.
wherein the glyoxalated copolymer is 0.25 to 4 weight %, preferably 1 to 3 weight %, most preferably 1.5 to 2.5 weight % based on total weight of the aqueous reaction medium; 
gdje je glioksilirani kopolimer 0,25 do 4 masena %, poželjno 1 do 3 masena %, najpoželjnije 1,5 do 2,5 masena % zasnovano na ukupnoj masi vodenog reakcijskog medija;